RE: Re: Moving up now25 Aug 2020 12:03
CEO’s welcome
I hope everyone has had the opportunity to enjoy the summer so far.
This August answers session is intended to be the last before the VAL201 headline results are released later
this quarter. I encourage readers to refresh your memories by glancing through our Scientific Program
Review, provided on 19 May 2020 at https://www.valirx.com/wp-content/uploads/2020/05/Valirx-Scientific- Program-Review-19th-May-2020.pdf to be familiar with the trial endpoints, and an up to date summary of
the trial.
I’m anticipating that there will be additional questions after the headline results are released, and will
endeavour to respond as promptly as possible. The traditionally quiet period over the summer break has been a bit different this year, but nevertheless,
we’ve been taking advantage of this time to continue to assess new projects for potential in-licensing, and
also starting to work on an updated website to further improve communications and transparency between
the Company and Shareholders.
Best wishes,
Suzy
Dr Suzanne Dilly
Chief Executive Officer
ValiRx PLC